Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sartorius Stedim Cellca Expands | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sartorius Stedim Cellca Expands

Biopharma provider purchases property in Science Park III of Ulm

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sartorius Stedim Cellca, based near Ulm in southern Germany, purchased property of more than 6,000 square meters at Ulm’s Science Park III at Eselsberg to build a new laboratory and office complex. The new facility, which will approximately double the company’s space, is scheduled to be completed by the end of 2019.

“Our new site’s proximity to universities and research institutes in Ulm’s Scientific Park offers an excellent environment to promote our growing business for which we are also seeking additional highly qualified staff,“ said Hugo de Wit, managing director, Sartorius Stedim Cellca. “Besides the advantages offered by this research environment, its conveniently accessible location was also decisive for us. We need to be within easy reach of our international customers.”

Sartorius Stedim Cellca develops and markets platform technologies, such as cell lines and associated services, for customers in the biopharmaceutical industry. Since 2015, the company has been part of the biopharma supplier Sartorius Stedim Biotech and currently employs 80 people.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics